Personalised medicine: from diagnosis through to treatment

The aim of this project is to individually tailor the treatment of patients with multidrug and extremely resistant tuberculosis, and to increase the rate of treatment success. To this effect, resistance testing must be incorporated into the diagnosis as early as possible. Individually tailored treatment necessitates biomarkers that provide precise information about the course of treatment success. Existing TB patient cohorts in Germany, Rumania, and Africa can help find and validate such biomarkers. Furthermore, DZIF scientists will analyse the role concomitant diseases and inflammation play in long-term treatment success.

Treating patients with multidrug-resistant tuberculosis individually
35 patients with multidrug-resistant and extensively drug-resistant tuberculosis (M/XDR tuberculosis) and 55 control patients with non-resistant tuberculosis were recruited during the first DZIF funding period. A further patient cohort was recruited from the Eastern European Study Site in Bucharest, and tuberculosis patients at the African Partner Institutions have also been included. With the help of these patient cohorts, the scientists will identify and validate biomarkers that optimise treatment on an individual basis.
Jan Heyckendorf, Research Center Borstel; Christoph Lange, Research Center Borstel; Andrea Rachow, University of Munich

Tuberculosis: concomitant diseases and their effect on treatment success Tuberculosis treatment duration and success are dependent on many parameters, including the occurrence of concomitant diseases, amongst other things. The DZIF scientist will follow up the cohort patients for at least six months, and analyse which treatment forms are associated with which diseases.
Contact: Andrea Rachow, University of Munich